Seaport Diagnostics, Inc.

DUBLIN--( BUSINESS WIRE )--The "Human Gene Sequencing Markets, Strategies & Trends - Forecasts by Application, by Technology, by Workflow, by Product, and by Country, with Executive and Consultant Guides - 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the opportunities now that sequencing has gone mainstream? The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out for five years. The report includes detailed breakouts for 14 countries and 5 regions. Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. Scope of the Report The Global Market for Human Genome Sequencing Global Market Overview by Country Global Market by Application - Overview Global Market by Technology - Overview Global Market by Workflow - Overview Global Market by Product - Overview Market Sizes by Application Hereditary Gene Sequencing Market NIPT Gene Sequencing Market Oncology Market Psychology Market WGES Gene Sequencing Market Pharmacogenomics Market DTC Gene Sequencing Market Research Gene Sequencing Market Other Application Market Market Sizes by Technology Sanger Sequencing Market NGS/2G Market 3G/Long Market Other Technology Market Market Sizes by Workflow Sequencing Market Sample Prep Market Analysis Market Market Sizes by Product Instruments Market Consumables Market Software & Services Market Vision of the Future of Human Gene Sequencing Key Topics Covered: 1 Market Guides 1.1 Human Gene Sequencing Markets - Strategic Situation Analysis & COVID Impact 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Gene Sequencing Definition In This Report 2.1.1 Gene Sequencing 2.1.2 Hereditary 2.1.3 Non Invasive Prenatal Testing 2.1.4 Oncology 2.1.5 Psychology 2.1.6 WGES 2.1.7 Pharmacogenomic 2.1.8 Direct to Consumer 2.1.9 Research 2.1.10 Other 2.2 The Genomics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.4 Methodology 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 2.6 Chromosomes, Genes and Epigenetics 2.6.1 Chromosomes 2.6.2 Genes 2.6.3 Epigenetics 2.6.4 Genetic Testing vs. Gene Sequencing 2.6.5 Cost and Pricing Practice 3 Global Listing of Sequencer Installed Base - Location & Contacts 3.1 Notes to Installed Base Listing 3.2 Illumina Installed Base 4 Market Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 Human Gene Sequencing -Markets, Examples and Discussion 4.2.1 Inherited Disease - Not what it used to be 4.2.1.1 Clinical and Research Lines Blur 4.2.1.2 Genetic Counselling - Not so simple anymore 4.2.1.3 The Genetic Blizzard - Issues of Access and Payment 4.2.2 Newborn Screening - The Standard of Care 4.2.2.1 Newborn Screening - Do Parents Want to Know? 4.2.3 NIPT - We've Only Just Begun 4.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS 4.2.3.2 NIPT in the Future - Beyond Inherited Disease 4.2.4 Oncology - Understanding Two Worlds 4.2.4.1 The Tumor - A Sequence of Sequencing 4.2.4.2 The Tumor - Biopsy and Liquid Biopsy 4.2.4.3 The Human Genome - Predisposition and Prognosis 4.2.5 Pharmacogenomics 4.2.5.1 Sequencing Not the Only Player 4.2.5.2 New Roles for Old Drugs - A Research Bonanza? 4.2.6 Direct To Consumer - More Than Meets the Eye 4.2.6.1 DTC - How Many Segments? 4.3 Industry Structure 4.3.1 Hospital's Testing Share 4.3.2 The Rise of the Sequencing Lab 4.3.3 Sequencing as a Commodity 4.3.4 Informatics 4.3.5 Instrument Manufacturer Role 4.3.6 Healthcare Industry Impacts - Still Struggling 4.3.7 Can the Healthcare Industry Adapt? 4.3.8 Genetic Counselling as an Industry 4.3.9 Sequencing Adoption and Cannibalization 5 Market Trends 5.1 Factors Driving Growth 5.1.1 New Diagnoses 5.1.2 Wellness and Prevention 5.1.3 Fertility Technology 5.1.4 Cancer - Screening, Management and Monitoring 5.2 Factors Limiting Growth 5.2.1 Increased Competition Lowers Price 5.2.2 Lower Costs 5.2.3 Healthcare Cost Concerns Curtail Growth 5.2.4 Wellness has a downside 5.3 Sequencing Instrumentation 5.3.1 Instrumentation Tenacity 5.3.2 Declining Cost of Instruments Changes Industry Structure 5.3.3 Long Reads - Further Segmentation 5.3.4 Linked Reads 5.3.5 New Sequencing Technologies 6 Human Gene Sequencing Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 Natera Files Suit Against NeoGenomics 6.3 Genomics England to Sequence 100K Newborns 6.4 Novigenix Raises $14M for NGS based Liquid Biopsy 6.5 LetsGetChecked Launching New PGx Service 6.6 Qiagen, Neuron23 Partner for NGS Diagnostic 6.7 Harbinger Health Technology Focused On Oncogenesis 6.8 Delfi Diagnostics to Develop Early Detection Test 6.9 Dante Labs to Introduce WGS to Italian Healthcare System 6.10 Invitae Neurodevelopmental Disorders Testing Service 6.11 Thermo Fisher Obtains CE Mark for Ion Torrent Genexus 6.12 Myriad Genetics Launches Suite of Cancer Tests 6.13 Oncocyte and Thermo Fisher Strike Partnership Deal 6.14 Illumina Partners With Precision Medicine to Assess Liquid Biopsy 6.15 Sysmex Inostics Develops Ultra-Sensitive Liquid Biopsy 6.16 Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Testing 6.17 Strata Oncology Trial Supports NGS Assay 6.18 NYU Gets FDA Clearance for Sequencing Test 6.19 NeoGenomics to Acquire Inivata 6.20 OncoDNA, Institut Curie Partner on Liquid Biopsy Research 6.21 Cancer Heritability Gene Set Expanded 6.22 Whole-Genome Sequencing Could Replace Cytogenetics 6.23 Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays 6.24 Ancestry Shutters Health Offering 6.25 Genetron Health Targeting Early Cancer Detection 6.26 Pan-European Initiative to Build Tools for Sharing Genomic Data 6.27 UK Government Unveils New Genomic Healthcare Strategy 6.28 Foundation Medicine Liquid Biopsy Gets FDA Approval 6.29 American Heart Association Develops Genetic Testing Guidelines 6.30 Yourgene Health Gets CE Mark for Iona NIPT Test 6.31 NorthShore Looks to Expand Genomics Integration Into Primary Care 6.32 Germline Results From Tumor Sequencing Guides Precision Therapy 6.33 FDA Clears Cancer Genomic Profiling From Personal Genome Diagnostics 6.34 BillionToOne Closes $15M Series A Follow-on Round 6.35 Clinics to Integrate Genomics Into Primary Care Appendices United States Medicare System: January 2022 laboratory Fees Schedule The Whole Genome Sequence of SARS-CoV-2 Profiles of Key Companies 10x Genomics, Inc. 23andME Inc. Abbott Laboratories AccuraGen Inc. Adaptive Biotechnologies Admera Health, LLC Agilent/Dako Akonni Biosystems Amoy Diagnostics Co., Ltd. Ancestry.com LLC Anchor Dx Arc Bio Arrayit Corporation ARUP Laboratories Astrid Bio Baylor Miraca Genetics Laboratories Beckman Coulter Diagnostics Becton, Dickinson and Company BGI Genomics Co. Ltd Bioarray Genetics Biocept, Inc. Biodesix Inc. BioFluidica BioGenex Biolidics Ltd bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc. Bio-Techne C2i Genomics Caris Molecular Diagnostics CellMax Life Centogene Cepheid (Danaher) Circulogene Clinical Genomics Color Genomics Complete Genomics, Inc. - A BGI Company Dante Labs Datar Cancer Genetics Limited Diasorin S.p.A. Element Biosciences Epic Sciences Epigenomics AG Eurofins Scientific Excellerate Bioscience Fabric Genomics Freenome FUJIFILM Wako Diagnostics Fujirebio Fulgent Genetics GE Global Research Gene by Gene, Ltd. Genedrive GeneFirst Ltd. Genetron Holdings Genewiz Genomics England Genomics Personalized Health (GPH) GenomOncology Genzyme Corporation Grifols Guardant Health Guardiome HeiScreen Helix Helomics Hologic HTG Molecular Diagnostics Human Longevity, Inc. iCellate Illumina Incell Dx Inivata Integrated Diagnostics Invitae Corporation Invivoscribe Karius Letsgetchecked Lexagene Lunglife AI Inc Macrogen MDNA Life SCIENCES, Inc. MDx Health Medgenome Meridian Bioscience Mesa Biotech (Thermo Fisher) Mesa Laboratories, Inc. miR Scientific MNG Labs NantHealth, Inc. Natera Nebula Genomics 448 NeoGenomics New England Biolabs, Inc. NGeneBio Novogene Bioinformatics Technology Co., Ltd. Omega Bioservices Oncocyte OncoDNA OpGen ORIG3N, Inc. Origene Technologies Oxford Nanopore Technologies Panagene Perkin Elmer Personal Genome Diagnostics Personalis Precipio PrecisionMed Promega Protagen Diagnostics Qiagen QuantuMDx Regeneron Pharmaceuticals Roche Molecular Diagnostics Roswell Biotechnologies Seegene SeLux Diagnostics Sema4 Holdings Sequencing.com Siemens Healthineers simfo GmbH Singlera Genomics Inc. Singular Genomics SkylineDx Standard BioTools Sure Genomics, Inc. Sysmex Sysmex Inostics Tempus Labs, Inc. Thermo Fisher Scientific Inc. Ultima Genomics Variantyx Volition Vyant Bio For more information about this report visit https://www.researchandmarkets.com/r/nqo2do About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions. Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices? The plummeting costs for Whole Genome Sequencing are creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years. All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered: Market Overview Market Participants Play Different Roles Instrument Manufacturer Independent lab specialized/esoteric Independent lab national/regional Independent lab analytical Public National/regional lab Hospital lab Physician lab DTC Lab Sequencing Labs Audit body Whole Genome Sequencing - Markets, Examples and Discussion Direct to Consumer - Two Approaches The New Age of Medical Information Dangers in DTC-WGS - Health Costs and Regulation Newborn and Prenatal - A Brave New World DTC - How Many Segments? Research Markets Research Funding and Capital Expense WGS Datasets Preferred Existing research repurposed Organism Wide Market Service Suppliers Respond Clinical - Understanding Germline and Somatic Somatic - Chasing Mutations and Pharmacogenomics Pathogen Testing The Hepatitis C Story Will the Microbiology Department Disappear? AgriBio - Big Business GMO is Here to Stay WGS Benefits and Risks The New Agriculture Industry Structure Hospital's Testing Share Economies of Scale Instrument Manufacturer Role Healthcare Industry Impacts - Still Struggling Can the Healthcare Industry Adapt? Genetic Counselling as an Industry WGES Adoption and Cannibalization The Meaning of Grail Market Trends Factors Driving Growth Diagnostic Factors Interpreting the Code Otherwise Changes in Agriculture Fertility Technology Comes of Age Pathogen Challenges Factors Limiting Growth Increased Competition Lowers Price Lower Costs Healthcare Cost Concerns Curtail Growth Wellness has a downside GMO Opposition Movement Sequencing Instrumentation Instrumentation Tenacity Declining Cost Changes Industry Structure LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS llumina ION Pacific Biosystems Roche SOLiD Oxford Nanopore What is Oxford Nanopore Sequencing? What can Oxford Nanopore Sequencing be used for? Oxford Nanopore Products Long Reads - Further Segmentation Linked Reads Targeted Sequencing Adopts CRISPR New Sequencing Technologies RNAP sequencing In vitro virus high-throughput sequencing Tunnelling currents DNA sequencing Sequencing by hybridization Sequencing with mass spectrometry Microfluidic Sanger sequencing Microscopy-based techniques WGES Recent Developments Genomics England, Aims to Sequence 100K Newborns Juno Diagnostics NIPT With At-Home Sample Collection Cardio Diagnostics Launches Genetic Cardio Risk Test Universal Genetic Testing in Breast Cancer Further Supported Aniling Gets CE-IVD Marks for Cancer Sequencing Tests MyOme Lands Investment for WGS GenomSys Gains CE Mark for New Genomic Analysis Software WGS Finds Lung Cancers Fall Into Molecular Subtypes Testing Distinguishes Benign Tumors From Precancerous Condition Plan to Sequence All Newborns in UK Clear Labs Raises $60M for Nanopore Sequencing Variantyx Expands Into Prenatal, Cancer Testing Whole-Genome Sequencing Aids Diagnosis in Stockholm Variantyx Raises $20M Nonacus WGS Service for SARS-CoV-2 Laboratories Center to Report Risk Scores in Clinical WGS Stanford Launches WGS for Cardiovascular Testing Illumina and NY Healthcare Partner on Clinical WGS Increased Adoption of WGS Needs Acceptance by Payors, Providers Veritas Intercontinental Completes €5M Series B Financing Round M2GEN and Discovery Life Sciences in Bioinformatics Agreement Genomics England Adopts Quantum ActiveScale Object Storage GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx NHS Wales Introduces WGS for Critically Ill Newborns Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test C2i Genomics to Launch Trials for MRD Detection Tech Roche Acquires Sequencing Company Stratos Genomics UK COVID-19 Sequencing Consortium Launches Invitae Acquires Three Companies: YouScript, Genelex, Diploid Experience From Centralized Genomic Medicine Lab MGI to Enable $100 Human Genome Nebula Genomics offers $299 WGS Team to Study Campylobacter Omics Veritas Genetics Restarts US Business NEOGEN, Gencove partner to advance animal genomics UK Whole-Genome Sequencing Project Obtains £200M WGS may help with disease outbreaks Veritas Cuts WGS Price by 40% Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing Machine-learning system used to diagnose genetic diseases Whole Genome Sequencing for healthy creates controversy Nebula Genomics Offers FREE Whole Genome Sequencing Profiles of Key Companies 10x Genomics, Inc Diagnostics 23andME Inc Abbott Laboratories AccuraGen Inc Adaptive Biotechnologies Admera Health, LLC Agilent/Dako Akonni Biosystems Amoy Diagnostics Co., Ltd Ancestry.com LLC Anchor Dx ARUP Laboratories Baylor Miraca Genetics Laboratories Beckman Coulter Diagnostics Becton, Dickinson and Company BGI Genomics Co. Ltd Bioarray Genetics Biocept, Inc. Biodesix Inc. BioFluidica BioGenex Biolidics Ltd bioMerieux Diagnostics Bioneer Corporation Bio-Rad Laboratories, Inc Bio-Techne C2i Genomics Caris Molecular Diagnostics CellMax Life Centogene Circulogene Clear Labs Clinical Genomics Complete Genomics, Inc. - A BGI Company Dante Labs Datar Cancer Genetics Limited Day Zero Diagnostics. Diasorin S.p.A Epic Sciences Epigenomics AG Eurofins Scientific Excellerate Bioscience Fabric Genomics Freenome FUJIFILM Wako Diagnostics Fujirebio Fulgent Genetics GE Global Research Gencove Genedrive GeneFirst Ltd Genetron Holdings Genewiz Genomics England Genomics Personalized Health (GPH) GenomOncology Genzyme Corporation Grifols Guardant Health Guardiome HeiScreen Helix Helomics Hologic HTG Molecular Diagnostics Human Longevity, Inc iCellate Illumina Incell Dx Inivata Invitae Corporation Invivoscribe Karius Lunglife AI Inc Macrogen MDNA Life SCIENCES, Inc MDx Health Medgenome Meridian Bioscience Mesa Biotech (Thermo Fisher) Mesa Laboratories, Inc miR Scientific MNG Labs NantHealth, Inc Natera Nebula Genomics NeoGenomics New England Biolabs, Inc Novogene Bioinformatics Technology Co., Ltd Omega Bioservices Oncocyte OncoDNA OpGen ORIG3N, Inc Origene Technologies Oxford Nanopore Technologies Panagene Pathogenomix Perkin Elmer Personal Genome Diagnostics Personalis Precipio PrecisionMed Promega Protagen Diagnostics Qiagen QuantuMDx Regeneron Pharmaceuticals Roche Molecular Diagnostics Roswell Biotechnologies Seegene Sequencing.com Siemens Healthineers simfo GmbH Singlera Genomics Inc SkylineDx Standard BioTools Sure Genomics, Inc Sysmex Sysmex Inostics Tempus Labs, Inc Thermo Fisher Scientific Inc Variantyx Volition Vyant Bio For more information about this report visit https://www.researchandmarkets.com/r/8jd5wb-genome-and?w=4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

More and more healthcare providers are recognizing the critical role that genomics software plays in the advancement of precision medicine. Investors are getting behind genomics as well, as evidenced by the $8.5 million seed financing round that Nest Genomics closed on Tuesday. The round was led by B Capital. Several other investors participated, including Y Combinator, Samsung Next, Maven Ventures and 23andMe CEO Anne Wojcicki. Nest, founded last year, is based in New York and has offices in San Francisco and Tel Aviv. The startup’s founders, Moran Snir and her husband Guy, have built a genomics company before. Their previous company, called Clear Genetics, was acquired by Invitae in 2019. “With the dramatic drop in sequencing cost and our increased understanding of the genome, genetics is becoming applicable to more and more patients,” said Moran Snir, who serves as Nest’s CEO. “But there is a last-mile problem with delivering genetic information to patients and integrating it into providers’ workflows. For example, patients who have a family history of cancer must be educated about how this could impact their health, she pointed out. In order to achieve the best treatment outcomes, providers must offer these patients genetic testing and personalize their care based on the results. That’s why Snir and her husband founded Nest. The company provides the software infrastructure needed for health systems, clinics, pharmaceutical companies and payers to launch and scale genomic programs. Nest’s platform has several electronic health record-integrated tools for providers, such as tools for patient triage, test ordering and clinical decision support for managing patients’ genetic results based on the latest clinical guidelines. Patients also need easy and secure access to their genetic information, Snir declared. Nest’s platform includes several features for patients, including personalized educational content, results sharing and reminders for screening. “We think of Nest as your home for genetic information.” Snir said. “Nest is a digital place to secure genetic results for life, so patients are empowered to access that data over time and use it with their providers to prevent or delay disease.” Nest’s software has already been adopted by several large health systems, according to the company’s press release. Snir declined to name which health systems these were, but said Nest will announce them later this year. Nest is certainly not the only company selling genomics software — there’s also companies like Helix and Seaport Diagnostics. In Snir’s view, Nest sets itself apart from the competition because its EHR–integrated platform can seamlessly integrate into a provider’s existing workflow. She also said Nest is unique because it combines clinical decision support with patient genetics engagement. Although the current fundraising environment is more challenging than it was in the past couple of years, Snir said there is still plenty of interest in the genomics space and Nest didn’t have too much trouble securing its seed financing. “My advice for other founders is to demonstrate a strong founder-market fit, make it clear that you are an expert in the field, and have a long-term vision,” she said. “Also, fundraising is distracting so try to make the process as short and efficient as possible so you can go back to building your company.”